image dons

je fais un don

Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study.

SAFA2022 (12-16 décembre) - Les experts répondent à vos questions
Trouble du rythme cardiaque responsable d'AVC - Dépistage gratuit et sans rdv !

Colloquium : Pathologies cardiaques de la femme (15 novembre 2022)
Replay prochainement disponible ici !!!

Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study.

Publié dans European Heart Journal, le 01 novembre 2009.

En savoir plus en consultant le site.

Auteurs : Montalescot G, Drexler H, Gallo R, Pearson T, Thoenes M, Bhatt DL.

Abstract

AIMS:

This study investigated the effects of irbesartan vs. enalapril, with early vs. late treatment, on markers of inflammation and ischaemic heart disease in patients with non-ST-segment elevation acute coronary syndrome (NSTEACS).

METHODS AND RESULTS:

Patients hospitalized with ischaemic symptoms and evidence of NSTEACS were randomized to early (at hospitalization) or late (at hospital discharge) treatment with irbesartan 150 mg/day followed by 300 mg/day on day 15 (n = 212) or enalapril 10 mg/day followed by 20 mg/day on day 15 (n = 217) to day 60. The primary endpoint was the change from baseline in high-sensitivity C-reactive protein (hs-C-reactive protein) at day 60; secondary endpoints included changes in troponin I, B-type natriuretic peptide, microalbuminuria, interleukin 6, myeloperoxidase, secretory non-pancreatic type II phospholipase A2, ischaemia-modified albumin, soluble CD40 ligand, matrix metalloproteinase-9, aldosterone, and blood pressure. High-sensitivity C-reactive protein levels were comparable in both the irbesartan and enalapril treatment arms. There were no treatment-related differences in any of the biomarkers measured. Changes in inflammatory markers were unaffected by the timing of treatment initiation. Both treatments were well tolerated, with no differences in major adverse cardiac events.

CONCLUSION:

In patients with NSTEACS, inflammatory markers decreased over time in both treatment arms, with no differences between irbesartan and enalapril.

Autres actualités

+

29/08/2022


Supraventricular arrhythmias more common than thought after...

Auteurs : Guedeney P, Laredo M, Zeitouni M, Hauguel-Moreau M, Wallet T, Elegamandji B, Alamowitch S, C...
+

10/09/2020


Culprit lesion location and outcomes in patients with multi-...

Publié dans EuroIntervention 2020 Sep 8: EIJ-D-20-00561. Auteurs : Hauguel-Moreau M, Barthélémy O, Farhan...
+

01/09/2020


COVID-19 acute myocarditis and Multisystem Inflammatory Synd...

Publié dans Chest 2020 Sep 7: S0012-3692(20)34359-2 Auteurs : Hékimian G, Kerneis M, Zeitouni M, Cohen-Au...